These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 21505316

  • 1. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).
    McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, Husnik M, Livant E, Price C, Jacobson C, MTN-004 Protocol Team.
    AIDS; 2011 May 15; 25(8):1057-64. PubMed ID: 21505316
    [Abstract] [Full Text] [Related]

  • 2. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.
    O'Loughlin J, Millwood IY, McDonald HM, Price CF, Kaldor JM, Paull JR.
    Sex Transm Dis; 2010 Feb 15; 37(2):100-4. PubMed ID: 19823111
    [Abstract] [Full Text] [Related]

  • 3. Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis.
    Chavoustie SE, Carter BA, Waldbaum AS, Donders GGG, Peters KH, Schwebke JR, Paull JRA, Price CF, Castellarnau A, McCloud P, Kinghorn GR.
    Eur J Obstet Gynecol Reprod Biol; 2020 Feb 15; 245():13-18. PubMed ID: 31812702
    [Abstract] [Full Text] [Related]

  • 4. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days.
    Cohen CR, Brown J, Moscicki AB, Bukusi EA, Paull JR, Price CF, Shiboski S.
    PLoS One; 2011 Jan 20; 6(1):e16258. PubMed ID: 21311578
    [Abstract] [Full Text] [Related]

  • 5. SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.
    Price CF, Tyssen D, Sonza S, Davie A, Evans S, Lewis GR, Xia S, Spelman T, Hodsman P, Moench TR, Humberstone A, Paull JR, Tachedjian G.
    PLoS One; 2011 Jan 20; 6(9):e24095. PubMed ID: 21935377
    [Abstract] [Full Text] [Related]

  • 6. "Tell Juliana": acceptability of the candidate microbicide VivaGel® and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study.
    Carballo-Diéguez A, Giguere R, Dolezal C, Chen BA, Kahn J, Zimet G, Mabragaña M, Leu CS, McGowan I.
    AIDS Behav; 2012 Oct 20; 16(7):1761-74. PubMed ID: 21863338
    [Abstract] [Full Text] [Related]

  • 7. Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035.
    Richardson BA, Kelly C, Ramjee G, Fleming T, Makanani B, Roberts S, Musara P, Mkandawire N, Moench T, Coletti A, Soto-Torres L, Karim SA, HPTN 035 Study Team.
    J Acquir Immune Defic Syndr; 2013 May 01; 63(1):120-5. PubMed ID: 23334506
    [Abstract] [Full Text] [Related]

  • 8. A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women.
    Mbopi-Keou FX, Trottier S, Omar RF, Nkele NN, Fokoua S, Mbu ER, Domingo MC, Giguère JF, Piret J, Mwatha A, Mâsse B, Bergeron MG.
    Contraception; 2010 Jan 01; 81(1):79-85. PubMed ID: 20004278
    [Abstract] [Full Text] [Related]

  • 9. A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis.
    Chen MY, Millwood IY, Wand H, Poynten M, Law M, Kaldor JM, Wesselingh S, Price CF, Clark LJ, Paull JR, Fairley CK.
    J Acquir Immune Defic Syndr; 2009 Apr 01; 50(4):375-80. PubMed ID: 19214122
    [Abstract] [Full Text] [Related]

  • 10. VivaGel (SPL7013 Gel): a candidate dendrimer--microbicide for the prevention of HIV and HSV infection.
    Rupp R, Rosenthal SL, Stanberry LR.
    Int J Nanomedicine; 2007 Apr 01; 2(4):561-6. PubMed ID: 18203424
    [Abstract] [Full Text] [Related]

  • 11. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.
    Delany-Moretlwe S, Lombard C, Baron D, Bekker LG, Nkala B, Ahmed K, Sebe M, Brumskine W, Nchabeleng M, Palanee-Philips T, Ntshangase J, Sibiya S, Smith E, Panchia R, Myer L, Schwartz JL, Marzinke M, Morris L, Brown ER, Doncel GF, Gray G, Rees H.
    Lancet Infect Dis; 2018 Nov 01; 18(11):1241-1250. PubMed ID: 30507409
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom formulations in women from Cameroon.
    Mbopi-Keou FX, Trottier S, Omar RF, Nkele NN, Fokoua S, Mbu ER, Giguere JF, Domingo MC, Piret J, Tsague L, Zekeng L, Mwatha A, Mâsse B, Bergeron MG.
    Contraception; 2009 Nov 01; 80(5):484-92. PubMed ID: 19835725
    [Abstract] [Full Text] [Related]

  • 13. A randomized controlled safety and acceptability trial of dextrin sulphate vaginal microbicide gel in sexually active women in Uganda.
    Bakobaki JM, Lacey CJ, Bukenya MI, Nunn AJ, McCormack S, Byaruhanga RN, Okong P, Namukwaya SW, Grosskurth H, Whitworth JA.
    AIDS; 2005 Dec 02; 19(18):2149-56. PubMed ID: 16284465
    [Abstract] [Full Text] [Related]

  • 14. Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa.
    van de Wijgert JH, Braunstein SL, Morar NS, Jones HE, Madurai L, Strickfaden TT, Moodley M, Aboobaker J, Ndlovu G, Ferguson TM, Friedland BA, Hart CE, Ramjee G.
    J Acquir Immune Defic Syndr; 2007 Dec 15; 46(5):538-46. PubMed ID: 18193495
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States.
    Montgomery ET, Noguchi LM, Dai JY, Pan J, Biggio J, Hendrix C, Isaacs K, Watts DH, Schwartz JL, Piper J, Beigi R.
    AIDS Behav; 2018 Feb 15; 22(2):402-411. PubMed ID: 28550377
    [Abstract] [Full Text] [Related]

  • 19. Acceptability of a carrageenan-based candidate vaginal microbicide and matching placebo: findings from a phase II safety trial among women in Chiang Rai, Thailand.
    Jones HE, Chaikummao S, van de Wijgert JH, Friedland BA, Manopaiboon C, Witwatwongwana P, Wankrairot M, Chantharojwong N, Kilmarx PH.
    J Womens Health (Larchmt); 2009 Jul 15; 18(7):1003-10. PubMed ID: 19575689
    [Abstract] [Full Text] [Related]

  • 20. The safety, persistence, and acceptability of an antiretroviral microbicide candidate UC781.
    Bunge K, Macio I, Meyn L, Noguchi L, Parniak MA, Schwartz JL, Moncla B, Hillier S.
    J Acquir Immune Defic Syndr; 2012 Aug 01; 60(4):337-43. PubMed ID: 22495787
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.